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Abstract
Background: The aggregates of a protein called, ‘Ab’ found in brains of Alzheimer’s patients are strongly believed
to be the cause for neuronal death and cognitive decline. Among the different forms of Ab aggregates, smaller
aggregates called ‘soluble oligomers’ are increasingly believed to be the primary neurotoxic species responsible for
early synaptic dysfunction. Since it is well known that the Ab aggregation is a nucleation dependant process, it is
widely believed that the toxic oligomers are intermediates to fibril formation, or what we call the ‘on-pathway’
products. Modeling of Ab aggregation has been of intense investigation during the last decade. However, precise
understanding of the process, pre-nucleation events in particular, are not yet known. Most of these models are
based on curve-fitting and overlook the molecular-level biophysics involved in the aggregation pathway. Hence,
such models are not reusable, and fail to predict the system dynamics in the presence of other competing
pathways.
Results: In this paper, we present a molecular-level simulation model for understanding the dynamics of the
amyloid-b (Ab) peptide aggregation process involved in Alzheimer’s disease (AD). The proposed chemical kinetic
theory based approach is generic and can model most nucleation-dependent protein aggregation systems that
cause a variety of neurodegenerative diseases. We discuss the challenges in estimating all the rate constants
involved in the aggregation process towards fibril formation and propose a divide and conquer strategy by
dissecting the pathway into three biophysically distinct stages: 1) pre-nucleation stage 2) post-nucleation stage and
3) protofibril elongation stage. We next focus on estimating the rate constants involved in the protofibril
elongation stages for Ab42 supported by in vitro experimental data. This elongation stage is further characterized
by elongation due to oligomer additions and lateral association of protofibrils (13) and to properly validate the rate
constants involved in these phases we have presented three distinct reaction models. We also present a novel
scheme for mapping the fluorescence sensitivity and dynamic light scattering based in vitro experimental plots to
estimates of concentration variation with time. Finally, we discuss how these rate constants will be incorporated
into the overall simulation of the aggregation process to identify the parameters involved in the complete Ab
pathway in a bid to understand its dynamics.
Conclusions: We have presented an instance of the top-down modeling paradigm where the biophysical system
is approximated by a set of reactions for each of the stages that have been modeled. In this paper, we have only
reported the kinetic rate constants of the fibril elongation stage that were validated by in vitro biophysical analyses.
The kinetic parameters reported in the paper should be at least accurate upto the first two decimal places of the
estimate. We sincerely believe that our top-down models and kinetic parameters will be able to accurately model
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the biophysical phenomenon of Ab protein aggregation and identify the nucleation mass and rate constants of all
the stages involved in the pathway. Our model is also reusable and will serve as the basis for making
computational predictions on the system dynamics with the incorporation of other competing pathways
introduced by lipids and fatty acids.
Background
As in many neurodegenerative diseases, AD is one in
which polypeptides aggregate to form amyloid deposits.
In AD, the aggregates of a protein called, amyloid-b
(Ab) peptide are strongly believed to be the cause for
neuronal death and cognitive decline [1]. Primarily two
forms of Ab, Ab40 and Ab42 (40 and 42 amino acids
respectively) are observed as the main components of
senile plaques in AD patients. Ab is known to aggregate
and form large fibrillar deposits. Among the different
forms of Ab aggregates, smaller aggregates called ‘solu-
ble oligomers’ are increasingly believed to be the pri-
mary neurotoxic species responsible for early synaptic
dysfunction.
The process of Ab aggregation is a nucleation-depen-
dent one that was inferred by the occurrence of a ‘lag-
phase’ prior to fibril growth showing a sigmoidal pattern
[2]. This process involves an initial rate-limiting step of
nucleation [3,4] followed by fibril growth [2,5]. A sche-
matic of the process is shown in Figure 1 (Inset).
Although the mechanism of nucleation and structure of
the nucleus are largely unknown, it has been argued
that the structure of the growing fibril is closely depen-
dent on the nature of the nucleus formed. Additional
evidence for a nucleation-dependant growth is that the
lag-phase can be eliminated by adding pre-formed
aggregates to monomers by a process called ‘seeding’
[6]. The efficiency of seeding, which directly reflects the
elongation rates, depends on the structure of the ‘seed’
itself [7].
Since the structure and shape of the seed is directly
linked to the nucleation process, the factors influencing
the latter are critical in amyloidogenesis of Ab. Unfortu-
nately, precise in vitro biophysical analyses of Ab aggre-
gation kinetics are very difficult to achieve. Along the
fibril formation pathway, one important intermediate,
called protofibrils were identified and characterized
[4,8-12] earlier. Protofibrils mainly differ from fibrils in
their size and solubility. While fibrils can be sedimented
with relatively smaller forces (19000g, 10min),
Figure 1 Kinetics of Ab aggregation pathway. Schematic diagram for Ab aggregation towards fibril formation. (Inset): Typical sigmoidal
growth curve of the aggregation process with three largely divided stages. The kinetic parameters associated with stage III (post-protofibril) are
examined in this study.
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protofibrils require substantially high sedimentation
forces and have smaller diameters than the fibrils [13].
These protofibrils have propensities to both elongate (by
monomer addition) as well as to laterally associate (pro-
tofibril-protofibril association) to grow into mature
fibrils. The rates for such process for Ab40 were also
experimentally determined [13]. A more elaborate analy-
sis by O’Nuallain and co-workers reported the kinetics
and thermodynamic parameters on Ab40 protofibril
elongation [14]. Besides these, few others reported on
the kinetics involved in Ab aggregation [5,9,15,16].
Nevertheless, there are almost no reports on the bio-
chemical analysis on the pre-nucleation states that
reiterates the difficulty involved in such analyses. Also,
the kinetics reported in these works report the aggregate
growth rate of protofibrils by curve fitting methodology,
and do not appropriately characterize the rate constants
of the biochemical reactions involved in these pathways.
Thus, these models and kinetic parameters cannot be
re-used to understand the interactions of the protofibrils
with the pre-nucleation stage oligomers (monomers,
dimmers etc.) and hence cannot give us an exact quanti-
fication of nucleation.
One way of overcoming this difficulty is to make theo-
retical calculations and predictions that can be at least
partially validated by experimental data. Based on this
principle, Lomakin and co-workers developed a detailed
model for determining the rates of nucleation and elon-
gation processes that was supported by light scattering
experiments [5,17]. In this model, the authors propose
the existence of ‘micellar’ forms of Ab that is in fast
equilibrium with the monomers. Despite these efforts a
thorough modeling of Ab aggregation via molecular-
level simulation mechanisms has been lacking. Ideally,
any model on Ab aggregation should be able to identify
the nucleation mass and the kinetic rate constants in
the different phases of aggregation: pre-nucleation, post-
nucleation and fibril elongation. In [25] (and the refer-
ences therein) the authors provide a detailed review on
various models of Ab aggregation which can be primar-
ily classified as curve fitted models. However, none of
these reports present a precise understanding of the
process, pre-nucleation events in particular, and have
not been computationally modelled either. As fibril for-
mation is often considered to be a stochastic process
with a large variation in nucleation rate among identical
macroscopic molecules, molecular-level simulations
would be essential. Furthermore, it is not realistic to
consider aggregation as an isolated event and there are
many different factors that can influence protein aggre-
gation in a physiological environment. Broadly, these
include molecules that may ‘interact’ with the protein of
interest besides others such as ionic strength, pH, tem-
perature etc stressing on the need for reusable models.
Only recently, Chung-Lee and colleagues have generated
a detailed molecular-level model of insulin aggregation
[18], which accurately tries to understand the biophysics
behind protein aggregation systems. However, their
model cannot be directly used to understand the
dynamics of Ab aggregation wherein, the nucleation
stage is itself unknown (more details on this are pro-
vided later).
In a bid to understand the complete dynamics of Ab
aggregation, we propose a divide-and-conquer strategy
in this paper by dissecting the Ab42 aggregation process
into three biophysically distinct stages (Figure 1, inset).
We justify the importance of understanding each of
these stages separately before we can put together a
complete model for the aggregation process. In this
paper, we present a detailed model of the third stage in
the aggregation process that involves protofibril elonga-
tion as well as lateral association to fibrils (Figure 1,
inset) and report the dynamics in terms of the kinetic
rates associated with this stage. Finally, we also discuss
how this model for the fibril elongation and association
processes can be used to build a complete simulation of
overall Ab42 aggregation towards fibril formation that
can accurately identify the rate constants of the other
two stages along with the nucleation mass associated
with them.
Results
Simulation of Ab fibril formation: Complexities in existing
models and biophysical understanding
Simulation of the kind we are presenting in this paper
has not been reported for Ab system. However, Lee and
co-workers have elegantly demonstrated such a model-
ling scheme for insulin aggregation, a system that is
fairly similar to Ab aggregation [18]. Although in their
report the authors have indeed presented data for Ab40,
many details were either absent or incomplete. There-
fore, in this section, we will review the insulin aggrega-
tion model presented in [18] to point out its limitations
and motivate our work.
Biophysical analysis of Ab42 aggregation.
First, we monitored the initial concentration dependence
of Ab42 peptides on the aggregation process in five dif-
ferent concentrations; 10, 25, 50, 75 and 100 M by thio-
flavin-T (ThT) fluorescence as shown in Figure 2A. ThT
is a dye known to exhibit fluorescence upon binding to
amyloid aggregates and has become a benchmark for
monitoring amyloid aggregation [19]. The objective of
this experiment was to estimate lag-times as well as rate
of the ‘post-nucleation’ part of aggregation and their
dependence on initial Abbconcentrations. To do so, the
raw data were fit to equation 1 as previously reported
[20], where lag-time is t0.5 – 2b and the rate constant
(kapp) is 1/b. This rate is assumed to be of the first
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order and more closely resembles post-nucleation kfb,1
in Figure 1 than pre-nucleation or protofibril elongation
stages. Moreover, this rate constant is indicative of the
net value for the overall fibril formation and does not
represent the individual rate constants for the mult-step
reactions in the pathway. The rates and lag-times
obtained from fitting the data in Figure 2A with equa-
tion 1 are given in Table 1. Since Ab aggregation is a
nucleation-dependant process, increase in its initial con-
centration will decrease the lag-time and concomitantly
increase the apparent rate of aggregation. Thus as
Figure 2 Characteristics of Ab aggregation as a function of initial monomer concentration. Concentration dependence of Ab aggregation
monitored by ThT fluorescence. A) Aggregation in five different initial concentrations of Ab buffered in 20 mM Tris, 150 mM NaCl, pH 8.0, at
37°C. The data were fit using eq 1. B) Relation between the calculated lag-times and initial Ab concentration and C) relation between rate of
elongation and initial Ab concentration.
Table 1 Lag-time and growth rate constants for Ab42







10 0.14 (± 0.03) 157.34 (± 15.3)
25 0.29 (± 0.15) 99.04 (± 12.1)
50 0.31 (± 0.18) 23.95 (± 7.2)
75 0.35 (± 0.21) 16.61 (± 6.3)
100 0.61 (± 0.31) 15.12 (± 6.2)
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expected, we observed the least lag-time and highest
apparent rate constants for 100 M followed by 75, 50,
25 and 10 M concentrations respectively. In addition,
there was an inverse linear correlation between loga-
rithm of Ab42 concentration and lag-time (Figure 2B).
The rate of aggregation was consistent with a first-order
kinetics based on the goodness of our fits and a fairly
linear dependency of the rate constants on Ab42 con-
centration (Figure 2C). These curve-fitted models closely
resemble the previous models on the aggregation pro-
cess and do not study the associated molecular-level
biophysics as discussed before.
F
a
e t t b
=
+ − −1 0 5[( )/ ].
(1)
Existing simulation on aggregation.
Molecular level simulations to model the aggregation
process typically approximate the pathway by a set of
biochemical reactions and compute the corresponding
reaction fluxes; next we need to formulate the differen-
tial equations for each oligomer concentration as a func-
tion of time. This will allow us to study the dynamics
(in terms of concentration change) of each of the oligo-
mers involved in the system. The existing model as well
as the models proposed in this paper primarily use ODE
based molecular level simulations to understand the
temporal dynamics and rate constants involved in the
pathway. Figure 3 shows the reactions considered along
Ab aggregation towards fibril formation [18].
Here, Ai’s denote the i-mers, n is the nucleation mass
and F denotes the fibrils. The authors in [18] make the
following assumptions to create this model for the insu-
lin aggregation system: a) monomer adds to i-mers until
the formation of fibrils, and b) nucleation involves
monomer addition as well as a structural change in the
oligomer An. Post-nucleation events involved during the
formation of fibrils are known to be faster than the pre-
nucleation stage as inferred from the sigmoidal growth
curve (Figure 1, inset). Since nucleation involves a con-
formational change that serves as a ‘seed’ for further
growth, the forward rate constants for post-nucleation is
a lot higher than the pre-nucleation ones (i.e., knu,n
+i>>knu,i). This relative difference in the rate constants
can also be attributed to the fact that the larger oligo-
mers produced after the nucleation stage are more likely
to interact with the monomers. Lee and co-workers
reported a ~108 fold difference in the rate constants for
the insulin aggregation pathways [18]. Also, since agita-
tion has been found to drastically shorten the lag-times
[23], knu,i and kfb,i are assumed to be diffusion-limited
[24]. It should be noted that according to [24], the rate-
limiting step is not the conformational conversion but
the chance association of a sufficient number of mono-
mers to form a stable, polymerization-competent
nucleus. This association of the monomers will be gov-
erned by their diffusivities. Following the Stokes-Einstein
equation, Lee and co-workers proposed that the diffusiv-
ity is roughly proportional to the inverted cubic root of
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The reverse reaction rate constants are assumed to be
independent of size i, and are abbreviated as knu- and
kfb- respectively. Based on this model, [18] also reported
the following estimates of the rate constants for the Ab
aggregation system:
knu,1= 1.38 ± 0.53 × 10
0 (h-1mM-1),
kfb,1= 1.37 ± 1.22 × 10
4 (h-1mM-1),
knu-= 1.01 × 10
-3 (h-1),
kfb-= 3.02 ± 2.64 × 10
2 (h-1).
The primary problem with this model was that it was
built for insulin in which the nucleation stage has been
well characterized to be less than n ≤ 10. Furthermore,
Lee and co-workers claimed the nucleation stage of
insulin as 6mers based on their comparisons with the
concentration curves of insulin aggregation as it mini-
mized the sum of squared errors (although the results
for this was not shown). However, the nucleation state
for Ab aggregation is not known precisely. It is expected
that the nucleation stage should be different for different
proteins that aggregate. Also, this model approximates
the post-nucleation stage by a simplified set of equations
without considering the two well-known (and possibly
different biophysically) mechanisms of fibril elongation:
through oligomer addition and lateral association
between protofibrils. Considering, the nucleation mass
of Ab aggregation to be 6mers, and using the rate con-
stants reported by Lee and co-workers as mentioned
above, we get the following comparisons (Table 2) in
the lag times from the simulated model and what we
have reported experimentally in Table 1.
As we find a large difference between the experimen-
tally observed and simulated lag times, we can infer that
for the Ab system, the nucleation mass and rate con-
stants might be quite different. Note that the mapping
constant to compare the concentration with the ThT
fluorescence intensities from experiments will not have
an effect on lag-time estimates and hence cannot
explain this difference. Lee and co-workers argue that to
quantify the concentration results better, nonlinear
effects from at least two possible sources must be
.
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Figure 3 Reactions towards fibril formation. Approximate set of reactions to model the entire Ab aggregation pathway. The reactions are
grouped into two stages: a) pre-nucleation stage to model the events occurring before nucleation; these set of reactions are slower and
assumed to occur primarily through monomer additions to higher end oligomers due to a higher initial concentration of monomers in the
system and b) the protofibril elongation stage consists of a faster set of reactions and is approximated by oligomer additions to protofibrils; we
do not consider protofibril-protofibril lateral association reactions in this phase as they are not completely captured by ThT fluorescence.
Table 2 Lag-time comparison between our Ab42 aggregation simulation and those generated using the model
reported in (18)
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considered: the non-ideal behavior of proteins at high
concentrations, and a possible experimental artifact
from the fluorescence ThT assay [18]. The activity coef-
ficients of proteins at high concentrations are typically
not constants and should be considered in the model
[21]. Secondly, as mentioned above, nonlinearity with
the ThT signal exists perhaps because ThT measure-
ments depend on the ThT:fibril formation, which
involves stoichiometric binding of both compounds [22].
This nonlinear relationship is unknown so the propor-
tionality constants based on each curve were assumed to
be different. This however is not a reasonable argument
as we discuss later.
Simulation complexity of the on-pathway
Thus in order to use the same model for the Ab system,
we need to estimate the following six unknown vari-
ables: knu,1, kfb,1, knu-, kfb- , n and b, where, b is the con-
stant that maps ThT fluorescence to concentration
estimates. It is certainly difficult to iterate through dif-
ferent values for each of these variables to get close to
the experimental plots (as done in [18]) due to the huge
solution space and finding the nucleation phase (i.e., n)
cannot be done independently without having estimated
the rate constants and mapping constant alongside. This
important part of the problem has not been discussed
sufficiently in [18] either.
Our approach in this paper is to employ a divide-and-
conquer strategy to bring down the number of variables
to be estimated together and thereby reduce the search
space as we discuss next. We first dissect the sigmoidal
fibril-growth curve into the following three sections
based on both experimental viability and the ease of
modeling (schematic shown in Figure 1 inset): (i) pre-
nucleation stage (ii) post-nucleation stage and (iii) pro-
tofibril elongation stage. The pre- and post-nucleation
stages can be well-approximated by the set of reactions
shown in Figure 3. However, the protofibril elongation
stage needs to combine both the post-nucleation and
lateral association stage reactions [13] that were not
considered in Lee et al’s model. However, considering
the lateral association mechanism actually increases the
complexity of the model as we now have to estimate
two more parameters in addition to the previous six: the
forward and backward rate constants for the lateral
association stage denoted by kla and kla- respectively.
Our goal is to estimate the post-nucleation rate con-
stants (kfb,1, kfb-, kla and kla) separately that can be veri-
fied by fibril seeding experiments without having to
consider the pre-nucleation stage variables. In this
paper, we report our estimates for these four rate con-
stants that were accomplished by building a different
reaction model, validated by in vitro data. This work
formulates a fundamental basis for our ultimate goal of
estimating all the kinetic parameters along the aggrega-
tion pathway towards fibril formation and identifying
the nucleation mass(es) for Ab aggregation.
Modeling the protofibril elongation stage
Biochemical analyses of Ab42 protofibril elongation
Synthetic Ab42 peptide was obtained from synthesis
facility at Mayo Clinic, Rochester, MN as a lyophilized
powder. Ab42 protofibrils were generated and isolated
as previously reported [11]. Freshly purified Ab42
monomers (100 µM) from size exclusion chromatogra-
phy buffered in 10 mM Tris, 50 mM NaCl, pH 8.0 was
agitated at room temperature for 48 h. The aggregation
was monitored using ThT fluorescence. The sample was
then centrifuged at 19000g for 12 min to spin out any
fibril that may have formed. The supernatant was then
fractionated by Superdex-75 size exclusion column to
isolate protofibrils from unreacted monomers and smal-
ler oligomers. The concentration of protofibrils was
measured by UV-Vis with a molar extinction coefficient
of 1450 cm-1 M-1 corresponding to Ab42. The elonga-
tion reactions were initiated by adding 2, 4 or 7 µM
protofibrils to 30 µM freshly purified, seed-free mono-
mers and with 10 mM ThT, in a fluorescence cuvette
(total volume of 100 µl) (Figure 4A). The initiation of
the elongation reaction is carried out under low salt
conditions (50 mM) to minimize any protofibril-protofi-
bril association. Hence, the addition of monomers to
protofibrils under these conditions will lead to an
increase in the size of protofibrils that can be monitoted
by ThT fluorescence. The results from this phase are
shown in Figure 4A. It should be noted that ThT will
exclusively give response to elongation reactions and
will not detect association reactions. This is because,
ThT is known to bind between two monomer units and
association reactions do lead to the formation of new
monomer-protofibril units, as opposed to the elongation
reactions.
ODE-based molecular level simulation of protofibril
elongation phase
The data thus obtained was modeled using Matlab’s
ODE toolbox. In particular, we have considered the set
of reactions shown in Figures 5 and 6. Here, A1 denotes
an Ab monomer and F are the protofibrils (of length
~1600-mers and average length ~64 nm)[11]. Also, Fi
denotes a protofibril with i number of Ab molecules
binding to it during the elongation phase.
Nichols and co-workers showed that typically the elon-
gation stage saturates with the formation of Fi’s with
length in the range 160-180 nm. Considering the average
Fi length, at saturation, to be equal to 170 nm, we can
compute the number of Ab’s attaching to a protofibril in
the elongation phase as: (1600x170/64 – 1600) = 2650.
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Furthermore, F denotes a standard protofibril of length
~1600-mers, whereas the Fi’s denote elongated protofi-
brils of length ~(1600+i)-mers.
Figure 5 shows the oligomer addition reactions which
are similar to the post-nucleation phase reactions con-
sidered in the model shown in Figure 3. However, we
only consider monomer addition in this phase so that
we can eliminate the nucleation mass estimates and
keep the number of parameters to be modeled simple.
This is certainly an approximation of the over-all oligo-
mer addition characteristics of the fibril elongation
phase, yet it is sufficient to appropriately estimate kfb,1
because of the following:
• The seeding experiment was intentionally done
over a shorter time period of 30-60 m.
• It is safe to assume that with 30 μM initial concen-
tration of Ab monomers, we will not have sufficient
number of nucleated oligomers in the system. The
pre-nucleation stage rate constants being a lot
slower than the post-nucleation ones and consider-
ing a sufficiently high initial monomer concentration
(of 30 μM), the number of dimeres, trimers and
other oligomers formed in the system will be rela-
tively low leading to lesser number of pre-nucleation
reactions.
• Considering the protofibril growth curve over a
shorter time span (we have considered protofibril
growth for 1 min, 2 mins and 5 mins to estimate the
rate constants), we can further eliminate the effects
of these lower-end oligomers in the system.
• The model assumes homogeneous distribution of
the oligomers and protofibrils in the system (that
can be simulated by constant stirring) to alleviate
the needs of considering the spatial effects and
molecular crowding phenomenon.
Hence, essentially we further dissect the fibril elonga-
tion growth curve due to seeding so as to eliminate the
effects of the other unknown parameters in the system.
This methodology can give us an estimate of kfb,1 and
kfb- without requiring us to estimate the other rate con-
stants and nucleation masses in the pathway. The com-
plete set of results for 30-60 mins will then be used to
estimate the lateral association stage rate constants only,
as we would have already estimated the post-nucleation
stage rate constants by then.
For each reaction shown in Figure 5, we have kfb,1
denoting the rate constant for the reaction leading to
the formation of Fi. Note that, in contrast to the post-
nucleation reactions shown in Figure 3, we do not have
to use the Stokes-Einstein equation to relate the forward
rate constants in the elongation stage. This is because
our assumption of monomer-additions to protofibrils
towards the beginning of the fibril elongation phase
does not require us to consider the effects of other oli-
gomers in the system. Also, the protofibril sizes being
relatively a lot larger than that of individual monomers,
the effects of protofibrils (of different sizes) on the diffu-
sivity of the reactants will be quite similar. Indeed the
Stokes-Einstein equation relating the rate constants in
the post-nucleation phase were related as follows (from
[18]): k k
i
fb i fb, ,= 1 3
1
, where the rate constants only
Figure 4 System dynamics from the biochemical experiments
conducted for protofibril elongation and lateral association.
Experimental results for Ab42 protofibril elongation and lateral
association. A) Three concentrations of isolated protofibrils (7, 4 and
2 µM) were elongated with freshly purified Ab42 monomers (30
µM). The reactions were monitored by ThT fluorescence. Both
mature fibrils and monomers (~ 4 µM) were used as negative
controls. B) Lateral association was initiated by the addition of 150
mM NaCl to the isolated protofibrils (4 µM) that was monitored by
Dynamic Light Scattering instrument. Protofibrils without salt was
used as a negative control. The data is plotted against count rate
which is directly proportional to the hydrodynamic radius of the
sample.
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differed due to the sizes of the smaller oligomers in the
system, which in our case are of the same size (i.e., i=1).
The rate constants for the reverse reactions are assumed
to be independent of size i, and abbreviated as kfb- fol-
lowing the discussion in [18]. Thus, we have three
unknown variables (kfb,1, kfb- and the mapping constant,
b) from the reaction set in Figure 5 that we need to esti-
mate by fitting to the experimental data.
The reactions shown in Figure 6 model the lateral
association stages. Ideally, lateral association should
involve the association of all possible sizes of protofibrils
to each other as illustrated in Figure 7. However, this
will exponentially increase the number of reactions that
need to be simulated and hence the simulation com-
plexity. To address this issue, we will model the lateral
association stage by the reduced set of reactions of Fig-
ure 6, where we restrict ourselves to only the standard
protofibrils (of length ~1600-mers) to react with the lar-
ger ones formed due to monomer additions from Figure
5. This assumption will again be valid towards the
beginning of the elongation phase (initial 30-60 mins)
wherein the number of standard protofibrils (i.e., F) and
monomers significantly outnumber the intermediate
protofibrils (i.e., Fi’s) and other oligomers (Ai, i=2,…,n)
in the system.
The actual reaction fluxes for each of the above men-
tioned models along with the corresponding differential
equations are reported in the Methods section.
Simulation results
In this section, we report the performance of our mod-
els and our estimates of the 5 unknown parameters for
the fibril elongation phase. All the simulations were exe-
cuted in Matlab’s ODE solver (we have used ode23s).
Our methodology involves iterating each of the forward
rate constants from 10-6,…108 and the backward rate
constants from 106,…10-8 at multiples of 10 (a total of
15x15=225 test cases for a particular estimate of b) to
identify the best combination that gives us the least
square error in comparison to the experimental esti-
mates. Before discussing the results, let us first explain
the mapping of ThT fluorescence intensities to the con-
centration curves of different species in the elongation
phase.
Comparing concentration curves to ThT fluorescence
intensities
The fluorescence intensity plots from experiments
essentially show the cumulative effect of all protofibrils
of a certain size (and beyond). It is well known that pro-
tofibril elongation is accompanied by an increase in ThT
fluorescence while lateral association does not [13]. This
is because as lateral association involves attachment of
two protofibrils (Figure 1), it does not result in the gen-
eration of new ThT binding sites, contrary to the elon-
gation mechanism. Therefore, we can safely assume that
a majority of ThT signals observed in elongation experi-
ments do not reflect any lateral association process.
Hence, from the simulation, one has to plot the cumula-
tive effects from all the protofibrils that can be mapped
directly to the experimental estimates. In order to do
this we will compute the following expression at each
value of the simulation time:
Figure 5 Protofibril elongation reactions - oligomer addition
phase. The oligomer addition phase in protofibril elongation is
approximated by monomer additions only. Due to the high initial
monomer and protofibril concentration in the system, these set of
reactions will primarily govern the system dynamics during the early
phases (~0-10 mins) of protofibril elongation.
Ghosh et al. BMC Bioinformatics 2010, 11(Suppl 6):S24
http://www.biomedcentral.com/1471-2105/11/S6/S24
Page 9 of 19
where [Fi] denotes the concentration of Fi, i denotes
the number of Ab molecules by which the fibril has elon-
gated and hence the contribution of the corresponding Fi
towards the fluorescence, and b is a constant scaling fac-
tor to map to the fluorescence sensitivity estimates.
Note that we have not considered the concentration of
the initial protofibrils (i.e., F) in the above expression
and the cumulative estimate is recorded only for the
elongated protofibrils. The major reason behind this is
the fact that although the average size of the protofibrils
is assumed to be ~1600-mers, it is only an average esti-
mate and hence it might not be correct to bring in its
effects by multiplying [F] by 1600. In fact, some of the
initial fibrils used in the experiments might already have
elongated (or laterally associated) even before the
experiments were conducted. To get around this pro-
blem, we have preprocessed the experimental data by
subtracting each fluorescence intensity (for each time
point) for every concentration by the minimum intensity
value for that specific initial concentration of protofi-
brils. This scales down the intensities to start from zero
and eradicates the effects of the initial protofibril con-
centration on the fluorescence intensity. Thus, the
intensity values as well as the cumulative concentration
(shown in the results) start from zero in the y-axis.
Also, as the experimental set-up (and hence the condi-
tions) for generating the intensities against different
initial concentrations was the same, it is unlikely that
the mapping constant b should be different for different
initial concentrations. This is in contrast to what has
been proposed in [18] to fit the curves conveniently to
experiments without considering the intricacies of the
system of equations. Our results have been generated
keeping the value of b constant and set to b=2000 that
gave the least square error after several additional itera-
tions of the Simple Model.
Simulation results and rate constant estimates
Estimates for monomer addition phase
We iteratively simulated the Simple Model first to esti-
mate the rate constants for the monomer addition
phase. To compare with the experimental results, we
only considered the fluorescence curves upto 1 min
(Figure 8A), 2 mins (Figure 8B) and 5 mins (Figure 8C)
as the effects from lateral association will be higher after
that. The best fit to the experimental plots (measured in
terms of least squared error) yielded the following esti-
mates: kfb,1=9.0x10
3 h-1mM-1, kfb-=4.5 x10
2 h-1 and
b=2000 respectively.
Figure 8A shows very good correspondence to experi-
mental estimates as expected (R2=0.99), as the lateral
association or higher-end oligomer formation effects are
minimal at the early phases of the elongation stage.
However, as the system is allowed to evolve for a larger
amount of time, the Simple Model becomes increasingly
less accurate (R2=0.86 for 2 mins and R2=0.7 for 5 mins)
due to these effects (as seen in Figures 8B and 8C). The
Figure 6 Protofibril elongation reactions – protofibril-
protofibril lateral association phase. The lateral association phase
is modelled by protofibril association to the elongated protofibrils
from the oligomer addition phase. We do not consider variable
length protofibril association in this phase to reduce the system
complexity. These set of reactions can model the lateral association
stage accurately in the initial phases (~0-10 mins) with high
concentration of standard protofibrils (i.e., F).
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R2 was computed by averaging out the R2 estimates for
each of the 3 concentrations considered for protofibrils
(i.e., 2 μM, 4 μM and 7 μM) for a constant 30 μM of
initial monomer concentrations.
Figure 8C points to another important aspect of the
system dynamics. We find that with lower initial protofi-
bril concentration, the effects of higher system time (~5
mins) are not as much as with higher concentrations.
This would logically mean that the results from the Sim-
ple Model worsen with higher system time because of
primarily the lateral association reactions (and not
higher-end oligomer addition to protofibrils) Note that,
with higher fibril concentration, the rate of monomer
consumption will be correspondingly higher and one
can argue that this will prohibit higher end oligomers to
be formed quickly in the system. However, the initial
monomer concentration being relatively quite higher
than that of the protofibrils, we should still have enough
monomers that escape the elongation phase and start
the oligomer formation process. This corroborates our
assumption in the Simple Model that the higher-end oli-
gomers do not have a pronounced effect in the fibril
elongation dynamics within the first few minutes.
Effects of the mapping constant b
As mentioned before all the simulation plots were gen-
erated keeping b constant (=2000) as we discussed the
importance of this parameter. If we vary b to better fit
the experimental plots for different estimates of initial
protofibril concentrations following the methodology in
[20], we do get a better R2 estimate; however, that
might not be practical.
Figure 9 shows the fit of the Simple model to the
experimental plots and we find a relatively high R2=0.99.
To generate the plot we have used the following esti-





b = 800 (for 2 μM initial protofibril concentration)
b = 1200 (for 4 μM initial protofibril concentration)
b = 1700 (for 7 μM initial protofibril concentration)
The initial monomer concentration was always fixed
to 30 μM as discussed before. The apparent non-linear-
ity in the mapping of concentration estimates to ThT
fluorescence (as discussed in [18]) seems to increase
with higher protofibril concentration. However, keeping
b constant at 2000, gave us the best fit for all the 3 pro-
tofibril concentrations used pointing to the fact, that
this non-linearity might not be directly proportional to
the initial concentrations and might be a vague
assumption.
Also, Figure 9 was generated using the Simple model
and we know that the set of reactions considered in
Figure 5 cannot accurately explain the dynamics of the
Figure 7 All possible lateral association reactions. This figure shows all possible lateral association reactions resulting from variable sized
protofibrils associating amongst themselves. These reactions illustrate the complexity of the lateral association phase that can potentially result
in an infinite set of reaction combinations.
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elongation stage for sure (because of the contribution
from the higher-end oligomers in the system and lateral
associations). Thus the mapping constant b is actually a
very important parameter that allowed us to fit our Sim-
ple model to the experimental plots (and get good
agreement with it) without precisely modeling all possi-
ble reactions in the pathway. Hence, until a physical
basis for varying the mapping constant is established, we
believe it to be prudent to use a constant b for any sub-
sequent work that requires a correspondence of concen-
tration estimates from simulations to ThT fluorescence
curves from experiments.
Estimates for lateral association phase from ThT
fluorescence experiments
To estimate the rate constants for the lateral association
phase, we simulated the Complete Model setting
kfb,1=9.0x10
3 h-1mM-1, kfb-=4.5 x10
2 h-1 and b=2000 as
approximated above and iterating through different values
for kla and kla- (225 test cases) as mentioned before.
Figures 10A and 10B shows the system dynamics with
the Complex Model and rate constant estimates of kla=
2.1 h-1mM-1 and kla-= 6.0 x10
-3 h-1, R2= 0.68 and kla=
9.0x10-1 h-1mM-1 and kla-= 6.0 x10
-3 h-1, R2= 0.6 respec-
tively. The low R2 estimates point to the importance of
considering all possible lateral association reactions as
we have showed in Figure 7 at the cost of very high
computational complexity. One important distinction of
Figure 8 System dynamics for 1-5 mins: Comparison between
simulation results using the simple model and experimental
plots generated by ThT fluorescence. Simulation vs experimental
data for protofibril elongation over 1 min (A), 2 min (B) and 5 min
(C). Green curves are the elongation data for isolated protofibrils (2
µM, lower curve; 4 µM, middle curve; 7 µM, upper curve) elongated
by freshly purified Ab monomers (30 µM). Simulation plot modeling
the elongation phase using simple model (blue).
Figure 9 System dynamics for 60 mins using simple model and
varying mapping constant, b. Simulation vs experimental data for
protofibril elongation for a longer time-span. Isolated protofibrils
were elongated using freshly purified Ab monomers (green).
Simulation plots modeling the elongation phase for longer time-
scales (blue) for kfb= 1.08x10
3 h-1mM-1 and kfb-= 1.2 x10
1 h-1. These
plots were generated by varying the mapping constant b for
different initial concentration of protofibrils as follows: b=800 for 2
µM of F, b=1200 for 4 µM of F and b=1700 for 7 µM of F.
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our models with the ones proposed in [18] is that we
are estimating the rate constants based on multiple
curves due to different initial concentrations which will
allow us to get closer to the actual rate constants
involved in fibril elongation. Alongside, we always keep
b constant as discussed above which is more practical.
The model in [18] gives higher R2 estimates only for a
particular initial concentration and fail for other cases
keeping b constant (as we have shown in Table 2).
We believe that the rate constants corresponding to
Figure 10B might be a better estimate (although it gives
a lower R2 value) of the lateral association rate constants
due to the nature of the curves. The model becomes less
accurate as the system time increases due to the other
lateral association reactions that we have not considered
and also due to oligomer addition to protofibrils effects.
These additional reactions will produce larger protofi-
brils quickly and could have pushed up the simulation
curves closer to that of the experiments. Also, as before,
the worsening is less for lower initial concentrations of
protofibrils as that will have a reduced effect on the lat-
eral association reactions.
Another interesting observation is that for a shorter
time span (1 min, 2 mins and 5 mins), the Complete
model performs quite well (based on the rate constants
estimated from Figure 10B) showing the validity of our
estimates (as can be seen in Figures 11A, 11B and 11C).
In particular, the R2 for a 1 min run of the system is
0.99 and only goes down to 0.95 and 0.87 for 2 mins
and 5 mins respectively. However, for longer time-spans,
the results from the Complete model worsen appreci-
ably. Specifically, as seen in Figures 10A and 10B, the
Complete model tends to overestimate the protofibril
effects on the ThT fluorescence. This is because of the
fact that the experimentally generated ThT fluorescence
intensity generally fails to capture the contributions
from the lateral association phase as discussed before.
Thus we need to validate our kinetic estimates for this
phase using Dynamic Light Scattering (DLS) experi-
ments as mentioned next.
Estimation of Ab42 protofibril-protofibril association
kinetics by DLS
Ab42 protofibrils were generated as mentioned before.
The reactions were performed on size-exclusion chro-
matography-purified protofibrils. The lateral association
reaction was initiated by addition 150 mM NaCl on 4
μM Ab42 protofibrils in 10 mM Tris, pH 8.0 in a total
volume of 70 μl and was monitored for 120 min on a
Zetasizer nano S DLS instrument (Malvern Inc., Wor-
cestershire, UK). The average count rate (Kcnts/s) was
plotted against time to generate Figure 12 (green). Elon-
gation of appropriate control without salt was also per-
formed that is indicated in the same figure indicating no
Figure 10 System dynamics for 60 mins: Comparison between
simulation results using the complete and simple models and
experimental plots generated by ThT fluorescence. Simulation
vs experimental data for protofibril elongation from the Complete
model. (A) results generated for kla= 2.1 h
-1mM-1 and kla-= 6.0 x10
-3
h-1. (B) kla= 9.0x10
-1 h-1mM-1 and kla-= 6.0 x10
-3 h-1. (C) simulation
results from the Simple model for longer time-span. Isolated
protofibrils were elongated using freshly purified Ab monomers
(green). Simulation plots modeling the elongation phase for longer
time-scales (blue).
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association. The results from these DLS experiments are
shown in Figure 4B.
A separate model for protofibril-protofibril lateral
association that can be validated by DLS experiments
In this section, we present a separate model targeted
towards the lateral association phase only. Note that as
mentioned in the DLS experimental set-up, this phase
does not involve monomers (and hence any protofibril
elongation reactions). Figure 13 shows the reactions
involved under the assumption of a homogeneous mix-
ture of 4 µM protofibrils used in the in vitro experi-
ments. The 10 different molecular species involved in
this phase are F, F1600, F3200, F4800, F6400, F8000, F9600,
F11200, F12800, and F14400. We assume that lateral asso-
ciation will result in at most a 10-fold increase in size of
the protofibrils within the first 2 hrs of observation such
that the system of reactions will not involve the forma-
tion of protofibrils beyond F14400. This is a rough esti-
mate though as we find approximately a 5-fold increase
in Kcnts/s measurements from DLS.
The reaction fluxes in this phase are denoted by Mi,j cor-
responding to the reaction between Fi*1600 and Fj*1600
forming F(i+j+1)*1600 for i=0,1,…,4 and j=i,i+1,…,8-i where
for simplicity of notations we denote F by F0. Thus, we get:
M k F F k F ii j la i j la i j, * * ( )* , , ,= [ ]⎡⎣ ⎤⎦ − ⎡⎣ ⎤⎦ ∀ ∈− + +1600 1600 1 1600 0 1 ..., , { , ,... }4 1 8{ } ∀ ∈ + −j i i i
Figure 11 System dynamics for 1-5 mins: Comparison between
simulation results using the complete model and experimental
plots generated by ThT fluorescence. Simulation vs experimental
data for protofibril elongation over 1 min (A), 2 min (B) and 5 min
(C). Isolated protofibrils were elongated as mentioned in Figure 8.
Simulation plot modeling the elongation phase using complete
model (blue).
Figure 12 System dynamics from the stand-alone lateral
association model presented in Figure13. Simulation vs
experimental data for protofibril-protofibril lateral association
reactions for 2 hrs. Isolated protofibrils were laterally associated and
their count rate (green) measured by DLS. Simulation plots
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The corresponding differential equations for this phase
are shown in Figure 14. Note that it is actually hard to
generalize these set of reactions and hence we will only
be using this model to validate our previously deter-
mined estimates of kla and kla-. The DLS experimental
results were preprocessed as before by subtracting the
minimum Kcnts/s value from all the data points. Corre-
spondingly, we use the same scheme for mapping the
concentration estimates to that of DLS and do not con-
sider the contributions from the initial protofibrils (i.e.,
F) as the summation starts from 1. However, in this
case, we only need to sum the weighted concentrations
of the 9 distinct molecular entities as shown above that
are formed in this system. Figure 12 shows the compari-
son of the DLS experimental results with the simulation
plot for kla= 9.0x10
-1 h-1mM-1 and kla-= 6.0 x10
-3,
b=6500 and a relatively high R2=0.89. Note that we have
used a different estimate for the mapping constant b in
this case as the DLS experiments are substantially differ-
ent from that for ThT fluorescence.
The lateral association model (from Fig 13) predicts a
linear increase in the count rate (and hence size) of the
protofibrils which is quite similar to the experimental
observations. An even better illustration of this can be
found in [13,26] where the authors have conducted a
number of light scattering experiments on Ab40 (having
similar characteristics as Ab42) and reported such linear
growth of protofibril size for ~100 hrs. Also, since pro-
tofibril growth also needs to saturate at some point of
time we used this model for a longer time-scale and
found the growth to saturate after about 3000 hrs
(results not shown). Such predictions are however hard
to validate experimentally.
Discussion
Contribution of our rate constant estimates to the overall
simulation of the Ab42 aggregation pathway
It is also worth mentioning that over-all the rate con-
stants for the lateral association phase is about 10,000
times slower than that of the monomer addition phase
and hence the model proposed in [18] might still be
able to simulate the complete dynamics of the Ab aggre-
gation system even though it does not explicitly con-
sider lateral association. Also, with our estimates of kfb,1
and kfb- we have reduced the number of unknown para-
meters and hence the complexity of this model that
makes it more plausible to estimate the nucleation mass
and the pre-nucleation stage rate constants.
In Figure 10-C, we have used the Simple model to fit
the experimentally generated fluorescence curves for a
longer time-span. As expected, these results are worse
than what we see from the Complete model, and actu-
ally points to the importance of considering the lateral
association reactions which was not done in [18]. How-
ever, our next endeavor of simulating the complete fibril
formation pathway (considering pre-, post-nucleation
and fibril elongation stages) might get prohibitively
complex in terms of computational requirements if we
are to consider the complete sets of reactions. Hence,
Figure 10-C approximates the complete fibril elongation
dynamics using the Simple model (and hence a reduced
set of reactions) for which the best fit was obtained for
kfb,1=1.5x10
3 h-1mM-1, kfb-=4.5 x10
1 h-1 and R2=0.58.
These estimates could be used to approximate the fibril
elongation phase with a reduced set of reactions while
simulating the entire fibril formation pathway.
Conclusions
In this paper, we have proposed a divide-and-conquer
strategy to estimate the fibril elongation dynamics of
the Ab protein aggregation system. In order to under-
stand the kinetics of the entire fibril formation pathway,
our strategy dissects the sigmoidal fibril growth curve
into 3 stages: pre-nucleation stage, post-nucleation stage
and fibril elongation stage. We have presented an
instance of the top-down modeling paradigm where the
biophysical system is approximated by a set of reactions
for each of these stages. In this paper, we have only
reported the kinetic rate constants of the fibril elonga-
tion that were validated by in vitro biophysical analyses.
Specifically, the time-line of the in vitro experiments on
fibril elongation was further subdivided to approxi-
mately identify the kinetics of the separate facets of pro-
tofibril elongation: oligomer addition stage
(approximated by monomer additions in this paper) and
lateral association stage. The kinetic parameters
reported in the paper should be at least accurate upto
the first two decimal places of the estimate. We sin-
cerely believe that our top-down models and kinetic
parameters will be able to accurately model the biophy-
sical phenomenon of Ab protein aggregation and iden-
tify the nucleation mass and rate constants of all the
stages involved in the pathway. Our model is also reusa-
ble and will serve as the basis for making computational
predictions on the system dynamics with the incorpora-
tion of other competing pathways introduced by lipids
and fatty acids.
Methods
Reaction flux and differential equations for the reaction
models
The fluxes for the set of reactions in Figure 5 can be
computed as follows:
G k F A k F
G k F A k F i
fb fb
i fb i fb i
1 1 1 1
1 1 1 2 3
= [ ][ ] − [ ]




, , , ,...,2650{ }
Ghosh et al. BMC Bioinformatics 2010, 11(Suppl 6):S24
http://www.biomedcentral.com/1471-2105/11/S6/S24
Page 15 of 19
Similarly, the fluxes for the reaction set in Figure 5 is
computed as:
H k F F k F
H k F F k F i
la la
i la i la i
1 1600
1 1599 2
= [ ][ ] − [ ]
= [ ][ ] − [ ] ∀ ∈
−
− − + , , ,...,3 1051{ }
After the kinetic schemes are established, the concen-
trations of various species are expressed as functions of
time. The temporal change of these species can be
derived from material balances and reaction kinetics.
We will consider the following two models to compute
the differential equations for each species in the aggre-
gation system: (i) Simple Model: in this case, we will
only be considering the reactions involved in Figure 5, i.
e., the monomer addition phase. The simple model will
be valid towards the beginning of the protofibril elonga-
tion phase (within the first 5 mins or so) before the lat-
eral association reactions take effect. (ii) Complete
Model: we will consider all the reactions from Figures 5
and 6 in this case. This model is more suited to under-
stand the dynamics of the system for a longer time-span
(30-60 mins) for which we have the experimental mea-
surements. Note that beyond 1 hr, the effects of higher
order oligomer addition to protofibrils as well as the
detailed lateral association reactions (from Figure 7) will
be more pronounced. The motivation behind the formu-
lation of the simple model is that we can reduce the
complexity of the system appreciably due to only 3
unknown parameters:kfb,1, kfb- and the mapping constant
b and these estimates will be used in the complete
model to estimate the remaining 2 variables: kla and kla-
following our divide-and-conquer strategy.
Differential Equations for the Simple Model
The first specie to be considered is the Ab monomers
whose rate of change is expressed in terms of its disap-
pearance (and hence the negative sign before the sum-
mation in the corresponding differential equation) due
to each of the reactions enlisted in Figure 5. The corre-
sponding differential equation for A1 depicting the rate











Similarly, the concentration change of the original




Note that the original protofibrils are only consumed
in the first reaction from Figure 5. However, for each
corresponding Fi in the system, they are produced by
the ith reaction and consumed by the (i+1)th reaction
leading to the following sets of differential equations:
dF
dt
G G ii i i= − ∀ ∈{ }+1 1 2 2649; , ,...,
Finally, the largest protofibril in the system (i.e., F2650)
is only affected by the last reaction in Figure 5, and its




The initial concentration of monomers is equal to the
amount of Ab added initially and along with the initial
fibril concentration (i.e., concentration of F) is the main
driving force for the downstream reactions defined in
Figure 5. The concentrations of the other species are
assumed to be zero at the start (i.e., [Fi]=0, i=1,…,2650).
The set of differential equations defined in the Simple
Model contain totally 2652 variables with equal number
of corresponding differential equations and initial condi-
tions. Thus, the system of differential equations is prop-
erly defined and ready to be solved once the values of
all parameters are specified. The 3 parameters that we
will estimate from this model (looking into the concen-
tration curves for the first 5 mins) are kfb,1, kfb- and the
mapping constant b.
Differential equations for the complete model
In this case the differential equations for each of the
species in the system need to consider additional reac-
tions introduced in Figure 6. Note that, the monomers
are still involved in all the reactions in Figure 5, how-
ever, none in Figure 6 involve them. Hence, the differen-
tial equation governing the rate of change of monomers











For the original protofibrils (i.e., F), the rate of con-
centration change can be calculated by taking into
account all the reactions involving F in Figure 6 along
with the first reaction from Figure 5. As a result, the
time derivative of F equals the consumption rate due to
all lateral association reactions, and the first monomer











The elongated protofibrils however follow a different
characteristic depending on their size making it
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necessary to consider them separately. F1,…,F1050 are
involved in the ith and (i+1)th reactions in the monomer
addition phase and also the (i+1)th reaction in the lateral
association phase. Hence the time derivative of protofi-
brils with size distribution in this range equals the for-
mation rate of the ith reaction from Figure 5 minus the
consumption rate of the (i+1)th reactions from each of
Figures 5 and 6 as follows:
dF
dt
G G H ii i i i= − − ∀ ∈{ }+ +1 1 1 2 1050; , ,...,
Protofibrils in the range F1051,…,F1599 however, are only
affected by the reactions in Figure 5 without any contri-
bution from the lateral association reactions. Hence the
time derivative of these protofibrils equals the formation
rate of the ith reaction minus the consumption rate of the
(i+1)th reactions from Figure 5 as follows:
dF
dt
G G ii i i= − ∀ ∈{ }+1 1051 1052 1599; , ,...,
Protofibrils in the range F1600,…,F2649 are again
affected by the ith and (i+1)th reactions in the monomer
addition phase and also the (i-1599)th reaction in the lat-
eral association phase. Hence the time derivative of
these protofibrils equals the formation rate of the ith
reaction minus the consumption rate of the (i+1)th reac-
tions from Figure 5 plus the formation rate of the
(i-1599)th reaction from Figure 6 as follows:
dF
dt
G G H ii i i i= − + ∀ ∈{ }+ −1 1599 1600 1601 2649; , ,...,
Finally the largest protofibril (F2650) is produced by
the last reactions from each of the two phases that we
have considered, and its time derivative equals the pro-
duction rate of the final reaction from each of Figure 5
and 6 as follows:
dF
dt
G H2650 2650 1051= +
Figure 13 All possible lateral association reactions considering at most 10-fold increase in the size of protofibrils. This figure shows all
possible lateral association reactions considering at most a 10-fold increase in the original protofibril size. Also, these set of reactions model the
lateral association phase explicitly without any oligomer addition taking place.
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As before, the initial concentration of monomers is
equal to the amount of Ab added initially and that of F
equals the initial protofibril concentration, while the
concentrations of the other species are assumed to be
zero to start with (i.e., [Fi]=0, i=1,…,2650). This set of
differential equations also contains 2652 variables with
equal number of corresponding differential equations
and initial conditions and hence is a properly defined
system. However, the Complete Model is more compu-
tationally challenging to solve (due to the additional
number of reactions introduced in comparison to the
Simple Model) and we found it difficult to iterate
Figure 14 Differential equations for the lateral association reactions considering at most 10-fold increase in size of protofibrils and no
fibril elongation reactions involved. This figure shows the differential equations governing the concentration change of the protofibrils
corresponding to the reactions shown in Figure 13. We assume a maximum 10-fold increase in size in the protofibrils and no oligomer addition
taking place in the system due to the absence of monomers.
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through multiple runs of this model to estimate all the 5
variables (kfb,1, kfb-, kla, kla- and b). Thus it was necessary
for us to define the Simple model first that will give us
an estimate of kfb,1, kfb- and b as it will only require us
to iterate the Complete Model lesser number of times
to estimate the remaining two parameters: kla and kla-.
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